EGFR and non-small cell lung carcinoma: The patient’s particular mutation was considered oncogenic and potentially targetable after review of the literature, where a case report reported a 12-months lasting response to osimertinib in a patient with NSCLC with the same 773-774HVdelinsLM EGFR alteration after failure of gefitinib.